

Jamie Horder

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9509811/jamie-horder-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

1,218
citations

17
h-index

30
g-index

30
ext. papers

1,480
ext. citations

6.9
avg, IF

4.26
L-index

#	Paper	IF	Citations
29	Five years of Nature Human Behaviour.. <i>Nature Human Behaviour</i> , 2022 , 6, 11-14	12.8	0
28	Atypical Neurogenesis in Induced Pluripotent Stem Cells From Autistic Individuals. <i>Biological Psychiatry</i> , 2021 , 89, 486-496	7.9	13
27	Xhosa schizophrenia genetics. <i>Nature Human Behaviour</i> , 2020 , 4, 237	12.8	
26	Serotonin and the heart of fear. <i>Nature Human Behaviour</i> , 2020 , 4, 129	12.8	
25	Toll of vaccine hesitancy. <i>Nature Human Behaviour</i> , 2020 , 4, 335	12.8	3
24	Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. <i>Neuropsychopharmacology</i> , 2019 , 44, 1398-1405	8.7	47
23	Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. <i>Translational Psychiatry</i> , 2019 , 9, 313	8.6	18
22	Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 114-119	5.8	24
21	GABA receptor availability is not altered in adults with autism spectrum disorder or in mouse models. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	26
20	Glutamate and GABA in autism spectrum disorder-a translational magnetic resonance spectroscopy study in man and rodent models. <i>Translational Psychiatry</i> , 2018 , 8, 106	8.6	111
19	Immune signatures and disorder-specific patterns in a cross-disorder gene expression analysis. <i>British Journal of Psychiatry</i> , 2016 , 209, 202-8	5.4	23
18	Neurexins and the tightrope of excitation/inhibition balance in the prefrontal cortex. <i>Journal of Neurophysiology</i> , 2016 , 115, 5-7	3.2	6
17	Chapter 12 GABA system dysfunction in autism and related disorders 2016 , 219-244		
16	Cortical and subcortical glutathione levels in adults with autism spectrum disorder. <i>Autism Research</i> , 2016 , 9, 429-435	5.1	14
15	Is there an excess of significant findings in published studies of psychotherapy for depression?. <i>Psychological Medicine</i> , 2015 , 45, 439-46	6.9	40
14	State-of-the-Art Analysis of High-Frequency (Gamma Range) Electroencephalography in Humans. <i>Neuropsychobiology</i> , 2015 , 72, 219-28	4	17
13	Autistic traits and abnormal sensory experiences in adults. <i>Journal of Autism and Developmental Disorders</i> , 2014 , 44, 1461-9	4.6	86

12	Glutamate/glutamine and neuronal integrity in adults with ADHD: a proton MRS study. <i>Translational Psychiatry</i> , 2014 , 4, e373	8.6	57
11	Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy ((1)H MRS). <i>Journal of Neurodevelopmental Disorders</i> , 2014 , 6, 42	4.6	8
10	The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. <i>Neuropharmacology</i> , 2013 , 68, 195-201	5.5	79
9	Reduced subcortical glutamate/glutamine in adults with autism spectrum disorders: a [(1)H]MRS study. <i>Translational Psychiatry</i> , 2013 , 3, e279	8.6	85
8	GABA system dysfunction in autism and related disorders: from synapse to symptoms. <i>Neuroscience and Biobehavioral Reviews</i> , 2012 , 36, 2044-55	9	268
7	Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. <i>Journal of Psychopharmacology</i> , 2012 , 26, 125-32	4.6	40
6	Recent advances in neuroimaging in autism. <i>Neuropsychiatry</i> , 2012 , 2, 221-229	1.8	4
5	"One in four" with a mental health problem: the anatomy of a statistic. <i>BMJ, The</i> , 2012 , 344, e1302	5.9	16
4	Placebo, prozac and PLoS: significant lessons for psychopharmacology. <i>Journal of Psychopharmacology</i> , 2011 , 25, 1277-88	4.6	36
3	Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 1103-13	5.8	67
2	Early effects of mirtazapine on emotional processing. <i>Psychopharmacology</i> , 2009 , 203, 685-91	4.7	60
1	Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. <i>Psychopharmacology</i> , 2009 , 205, 85-91	4.7	59